Hyderabad, Nov 12 (UNI) Dr Reddy’s Laboratories Ltd on Thursday announced the launch of Succinylcholine Chloride Injection USP, 200 mg/10 mL (20 mg/mL), Multiple-Dose Vials a therapeutic equivalent generic version of Quelicin® (Succinylcholine Chloride) in the US market.
It was approved by the US Food and Drug Administration (USFDA), Hyderabad-based pharmaceutical giant said in a release here.
The Quelicin® brand and generic market had US sales of approximately $74.8 million MAT for the most recent twelve months ending in September 2020 according to IQVIA Health.
Dr Reddy’s Succinylcholine Chloride Injection USP, 200 mg/10 mL (20 mg/mL), is available in multi-dose vials.
